Any patients any patients access to care in the way.

Researchers measured patients’ access to look at the distance they traveled to be treated and the lapsed time between diagnosis and initiation of chemotherapy care. The Medicare Modernization Act took issue with the fact that oncologists were often reimbursed too much – sometimes as much as three times what they had paid – for the chemotherapy drugs they give their patients and subsequently doctors saw those reimbursement payments fall, said Kevin Schulman, director of the DCRI center for Clinical and Genetic Economics, and senior investigator for this study. The concern was that patient care would suffer if doctors practices practices or scale back, making it necessary for patients to travel farther or go to inpatient facilities for treatment.

After Curtis, the median time patients waited to begin chemotherapy after diagnosis was 28 days and not change significantly for any of the treatment settings between 2003 and 2006.It is possible that the long-term effects of lower reimbursement easily easily, Curtis said, but now it looks like the fear of the law, the critics have not materialized that patients are that patients are affected this from the impact legislation. ‘We have learned in rural areas in rural areas have wait longer to get their chemotherapy after diagnosis start tends – their waiting times of up to five days increased from 2003 to 2006, ‘said Curtis. ‘Whether this is something that has a negative impact on patient outcomes could impact, is still unknown, but it is something that we should pursue further. ‘..Pediatric pediatric submissions for Prevenar filed submitted more than 50 countries spanning six continents. Prevenar 13 was two countries in two countries, to Chile, said first in July 2009. Prevenar 13 was is also being investigated in global Phase 3 clinical studies in adults, with regulatory submissions expected in 2010.